Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Top Health-Care Sector Stock Picks

|Includes: AET, AGN, AMGN, ANTM, Baxter International Inc (BAX), BDX, BIIB, EKTAF, FMS, GILD, GRFS, GSK, HCA, MRK, NVS, PFE, TEVA, UNH

Healthcare Stocks

Health Care: 3 Picks in a More Expensive Sector by Morningstar Investment Research

Despite the sector looking slightly overvalued overall, we still see stocks that offer attractive valuations across the different industries.

Although we view the health-care sector as slightly overvalued in aggregate, some stocks still look undervalued, including Merck (NYSE:MRK), Actavis (NASDAQ:ACT), and Baxter (NYSE:BAX).

Even though several years have passed since the worldwide economic downturn, overall health-care utilization remains tepid. But we see early signs of improvement partly spurred by health-care reform in the U.S., and we don't see the U.S. Supreme Court striking down the reform.

Mergers and acquisitions still continue at a rapid pace, as large conglomerates are looking for growth avenues and opportunities to cut costs, partially through lowering taxes.

Drug development in specialty-care areas, such as oncology, is increasing the productivity of drug and biotech companies, with several recent launches with very high prices reminding the investment community of the strong moats of large pharmaceutical and biotech firms.

In aggregate, the valuation of the health-care sector has risen to slightly exceed our fair value estimates. However, we still see several stocks that offer attractive valuations across the different industries. In the table below, we highlight a few of our top picks. However, we believe the current environment for health care continues to lend itself to a stock-pickers' market rather than a focus on industries.

Although the economic downturn passed several years ago, health-care utilization remains tepid, but recent signs are pointing to a pickup of the market. Historically, a lag of a couple of years tends to follow a recession before health-care spending returns. However, the magnitude of the recession and increasing cost-sharing with patients has delayed a sharp rebound in health-care use. The increase in U.S. hospital admissions starting in the second quarter of 2014 suggests a turning point in health-care usage; U.S. health-care reform is likely driving part of the uptick. With the mandated health-care insurance and expanded government insurance in the U.S., more people are seeking treatment. We expect a continual, gradual increase in demand for health care, but probably not a return to 2007 levels anytime soon.

Much has been written about the recent U.S. Supreme Court case challenging the Affordable Care Act on grounds that the federally run insurance exchange violates the ACA language, which says exchanges should be run by the state. We don't think the court will overturn that key provision because: 1) the spirit of the ACA language is not violated by the federally run exchanges, and 2) the four plaintiffs supporting the challenge have shown questionable, if any, harm by the federal exchange.

If the challenge wins, about 3% of the U.S. population could lose insurance, which would probably force the U.S. government to step in with some sort of support. However, if no support was implemented, the industries most negatively affected would be hospitals and managed care organizations. To a lesser extent, all the other health-care industries would be hurt, too, but the magnitude would probably be less than a 1% hit to sales for the majority of health-care companies.

In the pharmaceutical and device industries, companies are acquiring and merging to increase their growth potential through creating scale, cutting costs, and focusing on key strategic areas. We see this trend with the pending acquisition of Allergan by Actavis. This trend is also evident with Valeant's (VRX) bid for Salix (which may subsequently get outbid by Endo (NASDAQ:ENDP)). Further, AbbVie's (NYSE:ABBV) bid for Pharmacyclics (NASDAQ:PCYC) also shows the strong need by AbbVie to redeploy capital to secure growth through eventual patent losses. Additionally, we believe the low debt costs and tax incentives are also fueling this strong wave of mergers and acquisitions.

Turning to innovation in health care, the focus of drug companies is shifting toward specialty-care areas, which should increase drug-development productivity and strengthen the moats for drug companies. The pipelines of the major biotech and pharmaceutical companies are focused on smaller patient populations in areas such as oncology. Further, despite treating smaller patient populations, these indications can turn into major blockbusters. Bristol's (NYSE:BMY) recent approval of Opdivo in lung cancer is a good example of a midsize patient population, but an annual price approaching $150,000 should turn the drug into a major commercial success.

Top Health-Care Sector Picks


Although competition is increasing for Advate, Baxter's highly profitable hemophilia A product, we think this diversified firm's competitive advantages remain strong and the stock looks undervalued. We think Baxter has earned a wide economic moat, stemming from economies of scale in plasma processing, injectable therapies, and dialysis products. Intangible assets--like Baxter's strong brands, patent protection, and pipeline productivity--also allow the firm to remain remarkably profitable in tough industries. More than 70% of Baxter's sales come from products with market-leading positions, and the safety and quality of its biologic therapies allow it to charge a price premium over competitors.

Elekta (EKTA)

We believe Elekta is well-positioned in the radiotherapy market, which has tremendous growth potential as improvements in technology, increasing awareness of the clinical benefits, and a favorable cost/benefit proposition should dramatically increase global adoption over the next decade. Further, we feel that Elekta carries a wide moat based on a solid position in a market that is characterized by high barriers to entry, high switching costs, and strong intellectual property. This field has evolved into a duopoly over the past decade with virtually no new entrants, and the main two players, Elekta and Varian (NYSE:VAR), have built durable franchises and are well-positioned for growth.


Despite some upcoming patent loses, we believe the market undervalues Merck's strong pipeline, led by cancer drug Keytruda. We project peak sales for Keytruda of $8 billion, well ahead of consensus expectations. Further, we expect several other pipeline drugs to develop into significant blockbusters, more than offsetting minor patent losses over the next five years. Further, several recently launched drugs are addressing therapeutic areas that have increasing demand trends, including diabetes, where Merck's leading DPP-IV is well-positioned to treat the growing disease.

Click here for a Free Trial of Morningstar Investment Research

Health Beauty Products Isla

Health and Beauty Products

Candle Charting Intensive Training

Steve Nisons Candlestick Charting Intensive Training and Software
for Profitably Trading Stocks Forex Futures Commodities

Use the CandleScanner trading software to automatically scan for profitable trading setups on any timeframe. Stock forex and futures candlestick trading courses to throughly understand how to profit from candlestick chart patterns. Free newsletter and live trading webinars. Steve Nison is the authority on trading and profiting using candlesticks.

Track n Trade Trading Software

Track n Trade CandleStick Auto-Recognition Plug-in
Quickly identify candlestick patterns without thinking. With Track 'n Trade, you have the ability to click, and select your favorite candle patterns, and have Track 'n Trade find, identify, and even auto-trade each signal through our famed Autopilot Trading System.

Van Tharp Institute
Van Tharp Institute

Van Tharp Institute
Investing Trading Home Study Programs & Live Seminars Workshops

Dedicated to cutting edge, high quality professional educational investing trading programs for traders and investors providing a road map for financial freedom. The finest investing trading education in the financial universe. Dr Van Tharp is one of the orginal Market Wizards, and referred to as the Traders Coach.

Seeking Alpha

Live Trading Seminars

Stock Option Forex Futures Training Seminars Webinars Workshops
Click Here For The Complete 2015 Schedule

Professional investors traders teaching successful low-risk high-reward
trade strategies. Power profit secrets for stocks, options, forex, futures
investing trading success. Or avail of Home Study Courses and or
Trading Softwares available to improve your investment returns.